Tyrosine kinase receptor — nuclear protooncogene interactions in breast cancer

1991 ◽  
pp. 249-273 ◽  
Author(s):  
Robert B. Dickson ◽  
David S. Salomon ◽  
Marc E. Lippman
Keyword(s):  
Breast Cancer ◽  
Tyrosine Kinase ◽  
Tyrosine Kinase Receptor

scholarly journals Evaluation of EphB4 as Target for Image-Guided Surgery of Breast Cancer

2020 ◽  
Vol 13 (8) ◽  
pp. 172
Author(s):  
Cansu de Muijnck ◽  
Yoren van Gorkom ◽  
Maurice van Duijvenvoorde ◽  
Mina Eghtesadi ◽  
Geeske Dekker-Ensink ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Tyrosine Kinase ◽  
Breast Tissue ◽  
Normal Breast Tissue ◽  
Normal Breast ◽  
Her2 Status ◽  
Image Guided Surgery ◽  
Tyrosine Kinase Receptor ◽  
Guided Surgery ◽  
Image Guided

Background: Targeted image-guided surgery is based on the detection of tumor cells after administration of a radio-active or fluorescent tracer. Hence, enhanced binding of a tracer to tumor tissue compared to healthy tissue is crucial. Various tumor antigens have been evaluated as possible targets for image-guided surgery of breast cancer, with mixed results. Methods: In this study we have evaluated tyrosine kinase receptor EphB4, a member from the Eph tyrosine kinase receptor family, as a possible target for image-guided surgery of breast cancers. Two independent tissue micro arrays, consisting of matched sets of tumor and normal breast tissue, were stained for EphB4 by immunohistochemistry. The intensity of staining and the percentage of stained cells were scored by two independent investigators. Results: Immunohistochemical staining for EphB4 shows that breast cancer cells display enhanced membranous expression compared to adjacent normal breast tissue. The enhanced tumor staining is not associated with clinical variables like age of the patient or stage or subtype of the tumor, including Her2-status. Conclusion: These data suggest that EphB4 is a promising candidate for targeted image-guided surgery of breast cancer, especially for Her2 negative cases.

scholarly journals An tyrosine kinase receptor as promising therapeutic target for triple negative breast cancer

Mastology ◽  
2018 ◽  
Vol 28 (s1) ◽  
pp. 44-44
Author(s):  
Joana D. R. Santos ◽  
◽  
Maria F. S. Cardoso ◽  
Carlos H. M. Castelletti ◽  
Nancy C. F. L. Ferreira ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Tyrosine Kinase ◽  
Triple Negative Breast Cancer ◽  
Therapeutic Target ◽  
Triple Negative ◽  
Tyrosine Kinase Receptor ◽  
Promising Therapeutic Target

scholarly journals Trastuzumab treatment in patients with breast cancer is associated with differential expression of the neurotrophic receptor tyrosine kinase receptor NTRK2.

2020 ◽  
Author(s):  
Shahan Mamoor
Keyword(s):  
Breast Cancer ◽  
Tyrosine Kinase ◽  
Differential Expression ◽  
Receptor Tyrosine Kinase ◽  
Growth Factor Receptor ◽  
Tyrosine Kinase Receptor ◽  
Breast Cancer Patients ◽  
Transcriptional Responses ◽  
Primary Tumors ◽  
Epidermal Growth

The mechanism of action underlying trastuzumab (Herceptin) function is ascribed to binding of the Fab region of trastuzumab to the extracellular domain of the human epidermal growth factor receptor (HER2) (1). The transcriptional responses that follow signals transduced after trastuzumab binding of HER2 are less well understood. We mined published microarray and multiplexed gene expression data (2, 3) to understand in an unbiased fashion genes most differentially expressed in the primary tumors of breast cancer patients treated with trastuzumab. We observed significantly increased and differential expression of the neurotrophic receptor tyrosine kinase receptor 2, NTRK2 (4, 5).

scholarly journals Variations in COMT and NTRK2 Influence Symptom Burden in Women Undergoing Breast Cancer Treatment

2017 ◽  
Vol 19 (3) ◽  
pp. 318-328 ◽  
Author(s):  
Erin E. Young ◽  
Debra Lynch Kelly ◽  
Insop Shim ◽  
Kyle M. Baumbauer ◽  
Angela Starkweather ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Tyrosine Kinase ◽  
Sleep Disturbance ◽  
Early Stage ◽  
Symptom Burden ◽  
Breast Cancer Diagnosis ◽  
Tyrosine Kinase Receptor ◽  
Patient Symptom ◽  
Chemotherapy Patients ◽  
Specific Symptoms

Women with breast cancer frequently report distressing symptoms during and after treatment that can significantly erode quality of life (QOL). Symptom burden among women with breast cancer is of complex etiology and is likely influenced by disease, treatment, and environmental factors as well as individual genetic differences. The purpose of the present study was to examine the relationships between genetic polymorphisms within Neurotrophic tyrosine kinase receptor 1 (NTRK1), Neurotrophic tyrosine kinase receptor 2 (NTRK2), and catechol-O-methyltransferase ( COMT) and patient symptom burden of QOL, pain, fatigue, anxiety, depression, and sleep disturbance before, during, and after treatment for breast cancer in a subset of participants ( N = 51) in a randomized clinical trial of a novel symptom-management modality for women with breast cancer undergoing chemotherapy. Patients were recruited at the time of initial breast cancer diagnosis and completed all survey measures at the time of recruitment, after the initiation of treatment (surgery and/or chemotherapy), and then following treatment conclusion. Multiple linear regression analyses revealed significant associations between NTRK2 and COMT single nucleotide polymorphism (SNP) genotype and symptom burden. Two COMT variants were associated with the specific symptoms of anxiety and QOL measures prior to the initiation of chemotherapy as well as pain interference and severity during and after treatment. Genotype at the NTRK2 SNP rs1212171 was associated with both sleep disturbance and fatigue. These findings, while exploratory, indicate that the genotypes of NTRK2 and COMT may contribute to relative risk for symptom burden during and shortly after the period of chemotherapy in women with early stage breast cancer.

scholarly journals The Receptor Tyrosine Kinase TrkA Is Increased and Targetable in HER2-Positive Breast Cancer

Biomolecules ◽  
2020 ◽  
Vol 10 (9) ◽  
pp. 1329
Author(s):  
Nathan Griffin ◽  
Mark Marsland ◽  
Severine Roselli ◽  
Christopher Oldmeadow ◽  
John Attia ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Tyrosine Kinase ◽  
Cell Lines ◽  
Kinase Inhibitor ◽  
Breast Cancer Cell Lines ◽  
Tyrosine Kinase Receptor ◽  
Her2 Positive ◽  
Her2 Positive Breast Cancer ◽  
Ductal Carcinomas ◽  
Positive Breast Cancer

The tyrosine kinase receptor A (NTRK1/TrkA) is increasingly regarded as a therapeutic target in oncology. In breast cancer, TrkA contributes to metastasis but the clinicopathological significance remains unclear. In this study, TrkA expression was assessed via immunohistochemistry of 158 invasive ductal carcinomas (IDC), 158 invasive lobular carcinomas (ILC) and 50 ductal carcinomas in situ (DCIS). TrkA was expressed in cancer epithelial and myoepithelial cells, with higher levels of TrkA positively associated with IDC (39% of cases) (p < 0.0001). Interestingly, TrkA was significantly increased in tumours expressing the human epidermal growth factor receptor-2 (HER2), with expression in 49% of HER2-positive compared to 25% of HER2-negative tumours (p = 0.0027). A panel of breast cancer cells were used to confirm TrkA protein expression, demonstrating higher levels of TrkA (total and phosphorylated) in HER2-positive cell lines. Functional investigations using four different HER2-positive breast cancer cell lines indicated that the Trk tyrosine kinase inhibitor GNF-5837 reduced cell viability, through decreased phospho-TrkA (Tyr490) and downstream AKT (Ser473) activation, but did not display synergy with Herceptin. Overall, these data highlight a relationship between the tyrosine kinase receptors TrkA and HER2 and suggest the potential of TrkA as a novel or adjunct target for HER2-positive breast tumours.

Sign in / Sign up

Export Citation Format

Share Document